Michael Kutryk

MD, FRCPC, PhD

Scientist, Keenan Research Centre for Biomedical Science

Biography

Dr. Kutryk received his MSc, PhD and MD degrees from the Faculty of Medicine at the University of
Manitoba. He completed Specialty Certification in Internal Medicine and Subspecialty Training in
Cardiology at the Royal Victoria Hospital and McGill University in Montreal, Canada. Dr. Kutryk’s training in
cardiology was followed by a four-year post-doctoral research and clinical training program in Interventional
Cardiology at Erasmus University and University Hospital Rotterdam – Dijkzigt. Dr. Kutryk is currently an
Associate Professor and Clinician Scientist at the University of Toronto, Adjunct Professor in the Faculty of
Engineering and Architectural Science at Ryerson University and Director of Interventional Cardiology
Research at St. Michael’s Hospital in Toronto, Canada. He leads a basic research lab at the Li Ka Shing
Knowledge Institute dedicated to translating basic science findings to clinical application. Dr. Kutryk’s areas
of expertise include endothelial progenitor cell biology, gene therapy for vascular diseases, cell based gene
therapy strategies, angiogenesis, and miRNA signaling in health and disease. His lab has been very
successful in taking promising new treatment strategies from concept through preclinical assessment,
through to major, multicenter clinical trials. Recently, his research has focused on tissue engineered
vascular grafts and cardiac valves and epigenetic regulation of genes related to Hereditary Hemorrhagic
Telangiectasia, a disease of disregulated angiogenesis.

Recent Publications

  1. Zhang, Q, Duncan, S, Szulc, DA, Kutryk, MJ. Antibody functionalized intravascular devices combined with genetically engineered endothelial colony-forming cells for targeted drug delivery: a proof-of-concept study. Eur J Pharm Biopharm. 2022; :. doi: 10.1016/j.ejpb.2022.11.015. PubMed PMID:36403885 .
  2. Zhang, Q, Cannavicci, A, Kutryk, MJB. Exploring Endothelial Colony-Forming Cells to Better Understand the Pathophysiology of Disease: An Updated Review. Stem Cells Int. 2022;2022 :4460041. doi: 10.1155/2022/4460041. PubMed PMID:35615696 PubMed Central PMC9126670.
  3. Cannavicci, A, Zhang, Q, Faughnan, ME, Kutryk, MJB. MicroRNA-132-3p, Downregulated in Myeloid Angiogenic Cells from Hereditary Hemorrhagic Telangiectasia Patients, Is Enriched in the TGFβ and PI3K/AKT Signalling Pathways. Genes (Basel). 2022;13 (4):. doi: 10.3390/genes13040665. PubMed PMID:35456471 PubMed Central PMC9027908.
  4. Zhang, Q, Wang, C, Cheema, ZM, Kutryk, MJ. An optimal non-viral gene transfer method for genetically modifying porcine bone marrow-derived endothelial progenitor cells for experimental therapeutics. Sci Prog. 2021;104 (3):368504211024113. doi: 10.1177/00368504211024113. PubMed PMID:34283683 .
  5. Zhang, Q, Wang, C, Cannavicci, A, Faughnan, ME, Kutryk, MJB. Endoglin deficiency impairs VEGFR2 but not FGFR1 or TIE2 activation and alters VEGF-mediated cellular responses in human primary endothelial cells. Transl Res. 2021;235 :129-143. doi: 10.1016/j.trsl.2021.04.005. PubMed PMID:33894400 PubMed Central PMC8328903.
  6. Cannavicci, A, Zhang, Q, Kutryk, MJB. Non-Coding RNAs and Hereditary Hemorrhagic Telangiectasia. J Clin Med. 2020;9 (10):. doi: 10.3390/jcm9103333. PubMed PMID:33080889 PubMed Central PMC7603193.
  7. Diestro, JDB, Bhindi, R, Te, JT, Parra-Farinas, C, Kutryk, MJ, Marotta, TR et al.. Dislodged Clot During Percutaneous Coronary Intervention: From the Heart to the Brain. Can J Neurol Sci. 2021;48 (4):547-549. doi: 10.1017/cjn.2020.212. PubMed PMID:32981551 .
  8. Boukhris, M, Potter, BJ, Fam, NP, Matteau, A, Graham, JJ, Gobeil, F et al.. Safety and Performance of the Orsiro Sirolimus-Eluting Stent in the Treatment of All-Comers Patient Population in Daily Clinical Practice. Cardiovasc Revasc Med. 2020;21 (11):1348-1354. doi: 10.1016/j.carrev.2020.04.021. PubMed PMID:32354583 .
  9. Jin, W, Zhang, Q, Wang, B, Pan, L, Qin, H, Yang, D et al.. Cascade screening for familial hypercholesterolemia-identification of the C308Y mutation in multiple family members and relatives for the first time in mainland China. BMC Med Genet. 2019;20 (1):173. doi: 10.1186/s12881-019-0901-0. PubMed PMID:31706281 PubMed Central PMC6842482.
  10. Stone, GW, Kappetein, AP, Sabik, JF, Pocock, SJ, Morice, MC, Puskas, J et al.. Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. N Engl J Med. 2019;381 (19):1820-1830. doi: 10.1056/NEJMoa1909406. PubMed PMID:31562798 .
Search PubMed

Affiliations & Other Activities

  • Scientist, Li Ka Shing Knowledge Institute, St. Michael’s Hospital
  • Staff Physician, St. Michael’s Hospital
  • Associate Professor, University of Toronto